H.C. Wainwright lowered the firm’s price target on Arrowhead Pharmaceuticals to $60 from $90 and keeps a Buy rating on the shares. The firm removed zodasiran from estimates until it learns more about the clinical development path forward for the program. The company’s plozasiran program in familial chylomicronemia syndrome is on track to become Arrowhead’s first approved drug, potentially in 2025, the analyst tells investors in a research note. The firm continues to find Arrowhead “very compelling” at current share levels.
next post